Rate My Professor Michael Veve

Veve's primary research interests include the implementation and assessment of novel antimicrobial stewardship interventions; epidemiology and outcomes of multi-drug resistant pathogens; antimicrobial optimization in specialized patient populations; and prevention and treatment optimization of infections due to injection-drug use. His areas of expertise are antimicrobial stewardship and public health practice. He has contributed chapters including "Infectious Diseases" (Chapter 33) and "Anti-infective agents" (Chapter 34) to The APhA Complete Review for Pharmacy, 13th edition (2022). Key peer-reviewed publications encompass "Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study" in The Lancet Infectious Diseases (2025); "Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa" (2020); "Cephalosporins: a focus on side chains and β-lactam cross-reactivity" (2019); and "Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement" (2024). Veve co-directs the PGY2/3 Infectious Diseases Pharmacy Fellowship in Antimicrobial Stewardship jointly offered by Wayne State University and Henry Ford Hospital. He was awarded a $55,000 grant by Blue Cross Blue Shield of Michigan for his study "Equity of Oral Antimicrobial Therapy in Hospitalized People with Injection-Drug use related Infection who elect for Self-directed Discharge: A Mixed-methods Study with Pilot Intervention."